Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients

Aim Serum Golgi protein 73 (sGP73) is a novel biomarker for hepatocellular carcinoma (HCC). However, there are few reports on the pattern of GP73 expression in the progression of benign liver diseases to precancerous lesions and HCC. This study aimed to investigate GP73 expression and its correlatio...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2013-11, Vol.43 (11), p.1199-1210
Main Authors: Shan, Shi-Gang, Gao, Ying-Tang, Xu, Yan-Jie, Huang, Yong, Zhang, Qin, Zhai, Dao-Kuan, Li, Jian-Biao, Wang, Feng-Mei, Jing, Xiang, Du, Zhi, Wang, Yi-Jun
Format: Article
Language:English
Subjects:
Golgi protein 73
hepatocellular carcinoma
liver diseases
prognosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Serum Golgi protein 73 (sGP73) is a novel biomarker for hepatocellular carcinoma (HCC). However, there are few reports on the pattern of GP73 expression in the progression of benign liver diseases to precancerous lesions and HCC. This study aimed to investigate GP73 expression and its correlation with clinicopathological parameters. Methods Tissue GP73 (tGP73) levels were detected in specimens of group A (n = 186) including HCC, peritumoral tissue (PTL), high/low‐grade hepatic atypical hyperplasia (AH), chronic hepatitis B (CHB) and normal controls (NC) by immunohistochemistry, and GP73 expression in group B (n = 159) and group C (n = 16) were detected by reverse transcription polymerase chain reaction and western blot, respectively. sGP73 levels were detected in subjects of group D (n = 287) by enzyme‐linked immunoassay. Results GP73 expression increased gradually from NC, CHB, PTL to high‐grade AH and HCC at both protein and mRNA levels (P 
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.12078